James Gaume
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1609970797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $3,285, more than ten times the $227 reported in 2019.
Across 414 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$965
- Lilly USA, LLC$909
- AstraZeneca$725
- Dexcom, Inc.$532
- Insulet Corporation$494
- Xeris Pharmaceuticals, Inc.$467
- plus $4K from 33 others
What the payments were for
- Food & beverage$7,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $965 |
| Lilly USA, LLC | 47 | $909 |
| AstraZeneca(2 entities) | 40 | $725 |
| Dexcom, Inc. | 57 | $532 |
| Insulet Corporation | 13 | $494 |
| Xeris Pharmaceuticals, Inc. | 22 | $467 |
| Amgen | 20 | $417 |
| Sanofi-aventis U.S. LLC | 21 | $312 |
| Bayer | 17 | $299 |
| Medtronic | 8 | $293 |
| Boehringer Ingelheim | 14 | $249 |
| Mannkind Corporation | 2 | $161 |
| Amryt Pharma Holdings Ltd | 7 | $159 |
| AbbVie | 8 | $157 |
| Ascensia Diabetes Care US Inc. | 6 | $139 |
| Cequr Corporation | 1 | $138 |
| Abbott | 7 | $129 |
| Corcept Therapeutics | 5 | $112 |
| Antares Pharma, Inc. | 6 | $100 |
| Amneal Pharmaceuticals LLC | 6 | $94 |
| Lifescan, Inc. | 5 | $86 |
| Recordati_rare_diseases_inc. | 4 | $79 |
| Radius Health, Inc. | 4 | $79 |
| Pfizer | 3 | $72 |
| Esperion Therapeutics, Inc. | 3 | $67 |
| GRT US Holding, Inc. | 3 | $66 |
| Zealand Pharma US, Inc. | 3 | $64 |
| Tandem Diabetes Care, Inc. | 3 | $62 |
| Merck | 3 | $61 |
| Novartis | 3 | $54 |
| Amarin Pharma, Inc. | 2 | $42 |
| Clarus Therapeutics Inc. | 3 | $42 |
| Ascendis Pharma Endocrinology Inc | 2 | $41 |
| Companion Medical, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$245
- CeQur Simplicity$138
- InPen$125
- AFREZZA$125
How this compares
$7,791 in reported general payments places this provider in the 60th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $143,059 |
| JardianceEmpagliflozin | 74 | $84,070 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $54,926 |
| FarxigaDapagliflozin Propanediol | 15 | $22,910 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $21,269 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $18,770 |
| Novolog FlexpenInsulin Aspart | 40 | $14,672 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $8,364 |
| SynthroidLevothyroxine Sodium | 98 | $7,909 |
| NovologInsulin Aspart | 26 | $7,841 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,744 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $4,802 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 38 | $3,527 |
| Levothyroxine Sodium | 270 | $2,686 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $2,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $965 | $150,900152 claims |
| Boehringer IngelheimJardiance | $249 | $84,07074 claims |
| AstraZenecaFarxiga | $725 | $22,91015 claims |
| AbbVieSynthroid | $157 | $7,90998 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $94 | $2,686270 claims |
| Sanofi-aventis U.S. LLCLantus | $312 | $2,63720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.